Clinical Trials Logo

Schistosoma Mansoni clinical trials

View clinical trials related to Schistosoma Mansoni.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03910972 Active, not recruiting - Schistosomiasis Clinical Trials

Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults

Start date: October 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The study will recruit up to 290 healthy adult males and non-pregnant females into a two-part clinical trial of a vaccine to protect against schistosomiasis caused by infection with S. mansoni. Two formulations of the Sm-TSP-2 vaccine will be tested: one using Alhydrogel® only, and one using Alhydrogel® plus AP 10-701, each at 3 different doses of antigen: 10mcg, 30mcg, and 100mcg. The first part of the study will be a Phase I dose-escalation safety and immunogenicity study followed by a Phase IIb trial in which a larger number of adults will be enrolled to assess the impact of the vaccine on infection with S. mansoni. The impact of the vaccine on infection with S. haematobium will also be assessed although this will be exploratory given that potential cross-protection against this species is only hypothetical at this point.